HUMAN EPIDERMAL GROWTH FACTOR 2 POSITIVE CARCINOMA OF BREAST

Clinical trials for HUMAN EPIDERMAL GROWTH FACTOR 2 POSITIVE CARCINOMA OF BREAST explained in plain language.

Never miss a new study

Get alerted when new HUMAN EPIDERMAL GROWTH FACTOR 2 POSITIVE CARCINOMA OF BREAST trials appear

Sign up with your email to follow new studies for HUMAN EPIDERMAL GROWTH FACTOR 2 POSITIVE CARCINOMA OF BREAST, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New drug combo aims to keep breast cancer from returning to the brain

Disease control Ongoing

This study is for people with advanced HER2+ breast cancer whose cancer has spread to the brain but is stable elsewhere. It tests if adding the drug tucatinib to their current standard treatment can help keep the brain tumors from growing back longer. About 48 participants will r…

Matched conditions: HUMAN EPIDERMAL GROWTH FACTOR 2 POSITIVE CARCINOMA OF BREAST

Phase: PHASE2 • Sponsor: Carey Anders, M.D. • Aim: Disease control

Last updated Mar 30, 2026 14:32 UTC

HUMAN EPIDERMAL GROWTH FACTOR 2 POSITIVE CARCINOMA OF BREAST

Get alerted when new HUMAN EPIDERMAL GROWTH FACTOR 2 POSITIVE CARCINOMA OF BREAST trials appear

New drug combo aims to keep breast cancer from returning to the brain